Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IB1001 for Niemann-Pick Type C Disease
NCT03759639Phase 2Completed
- Sponsor
- IntraBio
- Start
- Sep 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, single-blind, single-arm trial of levacetylleucine in Niemann-Pick disease type C (NPC), sponsored by IntraBio. Primary endpoint: Clinical Impression of Change in Severity at 6 weeks. Started Sep 2019; status: completed.
02
Drugs
levacetylleucine
03
Conditions
Niemann-Pick disease type C (NPC)
Beyond the preview
Go deeper on NCT03759639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03759639.